Abstract:
본 발명은 안과용 수술장치, 이의 제어방법 및 이를 이용한 수술방법에 관한 것으로, 레이저를 생성하는 광원, 상기 광원에서 생성된 상기 레이저의 파라미터를 변환하는 광 변환부, 상기 광원에서 생성된 상기 레이저의 전달 경로를 형성하는 광 전달부, 상기 광 전달부의 단부에 형성되어 외부로 광을 조사하는 광 조사부 그리고, 수정체의 전낭을 절개하기 위한 제1 작동 모드, 상기 수정체의 핵 부위를 절개하기 위한 제2 작동 모드 및 각막을 절개하기 위한 제3 작동 모드에 따라 상기 광 변환부 및 상기 전달부를 제어하는 제어부를 포함하고, 상기 제어부는 각각의 작동 모드에 따라 상기 광 조사부를 통해 조사되는 레이저의 출력, 펄스 파형 또는 조사 패턴 중 적어도 어느 하나가 상이한 특성을 갖도록 제어하는 것을 특징으로 하는 안과용 수술장치 및 이를 이용한 수술방법과 이의 제어방법을 제공한다.
Abstract:
An OCT device having a lens for photographing cornea according to the present invention selectively photographs not only cornea and retina by adding a lens for photographing cornea, in an OCT device optically designed for photographing retina, and by adding a mechanism which selectively inserts and extracts a lens for photographing cornea between an object lens and the branch point of a camera light path and an OCT light path, but also prevents an increase in the size of the OCT device due to the addition of a lens for photographing cornea and a mechanism.
Abstract:
An optical coherence tomography (OCT) device having a Mire ring light source enables a Mire ring light source for irradiating measuring light of a ring shape on a cornea of an eye to be installed around an objective lens in a ring shape. Furthermore, the OCT device is capable of: adjusting an operation distance between an OCT unit and the eye to display a ring by a limited light source and a point by a unlimited light source at the same position in a surface image of the eye photographed by a camera; adjusting a focus between the OCT unit and the eye to minimize the thickness of the ring by the limited light source; and adjusting the center between the OCT unit and the eye to match the center of the ring by the limited light source with the center of a pupil of the eye. Therefore, the OCT device can automatically adjust the operation distance, the focus, and the center ring between the OCT unit and the eye of a patient, thereby improving reliability when the cornea or the retina is photographed, as well as improving user convenience.
Abstract:
PURPOSE: Prox 1 siRNA which is specific to a lymphatic endothelial cell is provided to suppress protein synthesis of Prox 1 and proliferation and growth of lymphatic duct, and to effectively treat corneal edema, clouding, and graft rejection. CONSTITUTION: An inhibitor of ophthalmic lymphatic duct contains Prox 1 gene siRNA selected from the group consisting of base sequences of sequence numbers 1-12. A composite of the Prox 1 gene siRNA and cationic lipid maximally suppresses Prox 1 protein expression by improving cell delivery efficiency and stabilizing Prox 1 siRNA. The cationic lipid is mPEG-Arg-Lys-dioleyl or 3-beta-[N-(N',N'-dimethylaminoethane)carbamoyl]cholesterol(DC-Chol). The cationic lipid is formed of a cathionic liposome, a micelle, an emulsion, or a nanoparticle. [Reference numerals] (AA) Lymphangiogenesis(%); (BB) Control group; (CC) Prox 1 siRNA
Abstract:
PURPOSE: A pharmaceutical composition containing secondary amine-substituted benzopyrane derivative is provided to prevent or treat macular degeneration. CONSTITUTION: A pharmaceutical composition for preventing or treating macular degeneration contains a compound of chemical formula 1 or pharmaceutically acceptable salt thereof as an active ingredient. The composition is used in the form of eye drops and the active ingredients are delivery to retina. Eye drops for preventing or treating macular degeneration contain the compound of chemical formula 1 or pharmaceutically acceptable salt thereof as an active ingredient. A pharmaceutical composition for preventing or treating macular degeneration contains (2R,3R,4S)-6-amino-4-[N-(4-chlorophenyl)-N-(1H-imidazole-2-ylmethyl)amino]-3-hydroxy-2-methyl-2-dimethoxymethyl-3,4-dihydro-2H-1-benzopyrane or pharmaceutically acceptable salt thereof as an active ingredient.